Loading
NASDAQHealthcareMedical - Devices
Latest quote
$3.04
−$0.45 · -12.89%
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Latest quote
$3.04
−$0.45 · -12.89%
After-hours
$3.0807
+$0.0407 · +1.34%
Oct 8, 5:44 PM ET
Regular session · ET · Market data may be delayed.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Day range
Current $3.04
52-week range
Current $3.04
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
37
Bearish
Risk
76
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Day range
Current $3.04
52-week range
Current $3.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 4.32K USD | 4.35K USD | 18.6K USD | 5.15K USD | 14.37K USD |
| Cost of goods sold | 133.12K USD | 129.84K USD | 101.21K USD | 29.71K USD | 34.46K USD |
| Gross profit | −128.8K USD | −125.49K USD | −82.61K USD | −24.56K USD | −20.08K USD |
| Research and development | 2.84B USD | 4.39M USD | 2.88M USD | 2.46M USD | 3M USD |
| Selling, general, and administrative | 5.58B USD | 3.84M USD | 3.34M USD | 3.63M USD | 1.69M USD |
| Operating expenses | 8.28M USD | 8.23M USD | 6.22M USD | 6.09M USD | 4.69M USD |
| Interest income | — | 87.8K USD | — | — | — |
| Interest expense | 753.04K USD | 500.45K USD | 354.08K USD | 243.17K USD | 371.62K USD |
| Depreciation and amortization | 131.35K USD | 127.96K USD | 95.13K USD | 135.45K USD | 26.57K USD |
| Operating income | −8.41M USD | −8.35M USD | −6.31M USD | −6.11M USD | −4.71M USD |
| Net income | −9.14M USD | −8.77M USD | −6.61M USD | −6.35M USD | −4.83M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
1.32% downsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 17, 2024 | 1:100 | — | — |
Effective May 17, 2024
1:100
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
